BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

Coherus BioSciences Inc. (NASDAQ:CHRS) and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) partnered to co-develop Junshi’s PD-1 inhibitor Tuoyi toripalimab in the U.S. and Canada, with Coherus gaining exclusive commercialization rights in both countries. Junshi...
BioCentury | Oct 3, 2019
Financial News

OrbiMed-led $80M series B to help Adicet bring its γδ cell therapies to the clinic

Adicet raised $80 million in an untranched series B round led by existing investor OrbiMed to bring its first three off-the-shelf γδ T cell therapies to the clinic. The company plans to submit in six...
BioCentury | Dec 19, 2011
Financial News

IntegenX completes venture financing

...Investors: Essex Woodlands Health Ventures; Domain Associates; QuestMark Partners; Greenspring Associates; Cross Creek Capital; RONAholdings; Samsung Ventures...
BioCentury | Dec 14, 2011
Financial News

IntegenX raises $40M in series C

...investor Essex Woodlands. Existing investors Domain Associates; QuestMark Partners; Greenspring Associates; Cross Creek Capital; RONAholdings; Samsung Ventures...
BioCentury | Nov 16, 2009
Company News

Microchip board of directors update

...Microfluidics Appointed: Jim Blair, partner at Domain Associates LLC; and Bill Byun, managing director of Samsung Ventures...
BioCentury | Nov 16, 2009
Financial News

Microchip completes venture financing

...Calif. Business: Microfluidics Date completed: 11/12/09 Type: Venture financing Raised: $18.1 million Investors: Domain Associates; Samsung Ventures...
BioCentury | Nov 13, 2009
Financial News

Microchip raises $18.1 million

...Calif.) raised $18.1 million in a series B round led by new investor Domain Associates. Samsung Ventures...
Items per page:
1 - 7 of 7
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

Coherus BioSciences Inc. (NASDAQ:CHRS) and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) partnered to co-develop Junshi’s PD-1 inhibitor Tuoyi toripalimab in the U.S. and Canada, with Coherus gaining exclusive commercialization rights in both countries. Junshi...
BioCentury | Oct 3, 2019
Financial News

OrbiMed-led $80M series B to help Adicet bring its γδ cell therapies to the clinic

Adicet raised $80 million in an untranched series B round led by existing investor OrbiMed to bring its first three off-the-shelf γδ T cell therapies to the clinic. The company plans to submit in six...
BioCentury | Dec 19, 2011
Financial News

IntegenX completes venture financing

...Investors: Essex Woodlands Health Ventures; Domain Associates; QuestMark Partners; Greenspring Associates; Cross Creek Capital; RONAholdings; Samsung Ventures...
BioCentury | Dec 14, 2011
Financial News

IntegenX raises $40M in series C

...investor Essex Woodlands. Existing investors Domain Associates; QuestMark Partners; Greenspring Associates; Cross Creek Capital; RONAholdings; Samsung Ventures...
BioCentury | Nov 16, 2009
Company News

Microchip board of directors update

...Microfluidics Appointed: Jim Blair, partner at Domain Associates LLC; and Bill Byun, managing director of Samsung Ventures...
BioCentury | Nov 16, 2009
Financial News

Microchip completes venture financing

...Calif. Business: Microfluidics Date completed: 11/12/09 Type: Venture financing Raised: $18.1 million Investors: Domain Associates; Samsung Ventures...
BioCentury | Nov 13, 2009
Financial News

Microchip raises $18.1 million

...Calif.) raised $18.1 million in a series B round led by new investor Domain Associates. Samsung Ventures...
Items per page:
1 - 7 of 7